Axplora has initiated global investments exceeding €100 million in 2025 to strengthen capabilities across its network of pharmaceutical manufacturing sites. The program includes €60 million for the ongoing expansion of its Mourenx, France site, alongside €35 million at Gropello, Italy, and €8.5 million at Vizag, India. Earlier this year, the company also expanded antibody-drug conjugate (ADC) production at its Le Mans, France facility.

The investments are part of a multi-year plan to enhance capacity, operational expertise, and delivery across Axplora’s nine sites worldwide. The Mourenx expansion, in particular, involves close collaboration with a customer on a complex project, with best practices being shared across the network to ensure consistent execution, reliability, and efficiency.

While high-growth modalities such as GLP-1 peptides and ADCs are a focus, small molecules remain the backbone of global pharmaceutical manufacturing. Axplora’s investment strategy reflects this balance: reinforcing large-scale small molecule capacity while also expanding in high-complexity areas. This approach aims to ensure resilience for essential medicines currently in demand, while preparing for advanced therapies that will shape the future of healthcare.

Martin Meeson, CEO of Axplora, said: “Announcing €100 million of investment this year is a landmark for Axplora – but more than just a number, it represents the trust our customers place in us and the scale of our commitment to them and their patients. Each euro invested is directed towards strengthening our capabilities, expanding our global network, and ensuring we are prepared to deliver the next generation of medicines with speed and reliability.”

Arul Ramadurai, chief commercial officer, added: “These investments reflect the trust our customers place in us and our commitment to working side by side with them. At Axplora, we dare to imagine a future where no patient waits for the medicines they need. That vision drives us to understand our customers’ needs and to build the scale, expertise, and capabilities that will help bring their breakthroughs to life faster and more efficiently.”